Contribution of fixed-dose combinations in the treatment of tuberculosis

##plugins.themes.academic_pro.article.sidebar##

Published Dec 7, 2016
Download
pdf
Vol. 94 No. 7 (2016): Issue Jul 2016

##plugins.themes.academic_pro.article.main##

Sonia Toujani
Boutheina Ben Safta
Nozha Ben Salah
Meriem Mjid
Yacine Ouahchi
Béchir Louzir
Jalloul Daghfous
Jouda Cherif
Nadia Mehiri
Majed Beji

Abstract

Abstract:
Background: The introduction of fixed-dose combinations (FDCs) of TB treatment in Tunisia is recent (July 2009). WHO and the National Tuberculosis Programme recommend the use of fixed-dose combination (FDC) tablets for the treatment of tuberculosis (TB). The effectiveness of ADF has been demonstrated, however the risk of relapse and tolerance were controversial.
Objective: Through a retrospective study, we evaluate, the contribution of FDCs compared with dissociated treatment (TD) (efficacy, tolerance and the occurrence of relapses).
Patients and methods: This is a retrospective study conducted in the Department of Pneumology la Rabta. Are included patients with pulmonary tuberculosis (TB) first attack. Two groups were studied: Group I (TC) treated between July 2009 and June 2011 who received ADF. Group II (TD) treated between July 2008 and June 2009 who received TB dissociated treatment.
Results: One hundred and seventy one patients were included: 122 in the TC group with an average age of 39.2 years and 49 patients in the TD group with an average age of 38.2 years. Male predominance was observed in the two groups (82/75.5%). The period of apyrexia was below 7 days at more than 80% of patients in the two groups. Sputum smears conversion were obtained between one and two months (median 52,8 vs 55,8 days) in both groups with no significant difference (p = 0.06). The rate of smears conversion at 2 months was 74% in TC group versus 65.3 % (p = 0.12). Eighty patients (65%) of the TC group and 29 patients (59%) of the TD group had one or more adverse effects to treatment without significant difference (p = 0.270). The most common adverse effects were those related to digestive system (17.2% vs 6.1%), liver toxicity (7.4% vs 4.1 %) and urticaria (9.8% vs 8.1%). The treatment successful rate was: 73.7 % in TC group and 77.5 % in TD group. There was no significant difference in treatment compliance, neither in relapse rate nor in the death rate.
Conclusion: This study demonstrated non-inferiority of the effectiveness of ADF with a comparable safety. Its effects in the prevention of relapse and resistance BK remain unproven.

Keywords:

Tuberculosis - antituberculosis drugs - Fixed-dose combinations

##plugins.themes.academic_pro.article.details##

References

  1. Guide de prise en charge de la tuberculose. Programme National de Lutte contre la Tuberculose. Direction de Soins et de Santé de Base 2014
  2. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull of Word Health Org 2001;79(1): 61-8.
  3. International Union Against Tuberculosis and Lung Disease/World Health Organization. The promise and reality of fixed dose combinations with rifampicin. Tubercle Lung Dis 1994;75:180-1.
  4. Moulding T, Dutt AK, Reichman LB. Fixed -dose combinations of antituberculous medications to prevent drug resistance. Annals of Internal Medicine, 1995, 122: 951-954.
  5. Panchagnula R, Agrawal S, KaulCL. Fixed dose combinations in the treatment of tuberculosis. Ind J Pharm Sci 2001;63:19.
  6. Pabloz Mendez Aetal.Global surveillance for antituberculosis drug resistance, 1994-1997. Worth Health Organisation -International Union Against Tuberculosis and Lung Disease. Working Group on Anti-Tuberculosis Drug Resistance Surveillance. New Engl Journal of Medicine, 1998, 338: 1641-1649.
  7. Organisation Mondiale de la Santé. Global Tuberculosis Control: Surveillance, planning, financing. Genève, OMS 2008 Project.
  8. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Vora MJ. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm 2001;228:53-67
  9. Singh S, MariappanTT, Shankar R, Sarda N, Singh B. A critical review of the probable reasons for the poor variable bioavailability of rifampicin from antitubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm 2001;228:5-17.
  10. Matiru R, Ryan T. The Global Drug Facility: a unique, holistic and pioneering approach to drug procurement and management. Bulletin of the World Health Organization 2007;85:348-53.
  11. Albanna AS, Smith BM, Cowan D, MenziesD.Fixed dose combination Anti-tuberculosis Therapy: A Systematic Review and Meta-Analysis. European Respiratory Journal 2013.
  12. Monedero I, Caminero J.A. Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review. Int J Tuberc Lung Dis 2011;15:433-9.
  13. Gravendeel J M, Asapa A S, Becx-Bleumink M, Vrakking H A. Preliminary results of an operational field study to compare side effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis 2003;83:183-6.
  14. Gravendeel J M, Asapa A S, Becx-Bleumink M, Vrakking H A. Preliminary results of an operational field study to compare side effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis 2003;83:183-6.
  15. Su W J, Perng R P. Fixed-dose combination chemotherapy (Rifater /Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. . Int J Tuberc Lung Dis 2002;6:1029-32.
  16. Jayawardena K A S, Samarathunga M. Baseline Characteristics of patients and the effects of fixed-dose combination chemotherapy on sputum conversion time in active pulmonary tuberculosis: A Preliminary Study in Kandy District, Sri Lanka. J Tuberc Lung Dis. HIV/AIDS 2008;5:1-6.
  17. Zhang LX, Kan GQ, Tu DH, Wan LY, Faruqi AR. Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis. CurrTher Res 1996;57:849-56.
  18. Munteanu I, Husar I, Didilescu C, Stoisescu IP. Considerations about the efficiency of treatment regimens of fixed Rifampicin-Isoniazid combinations in pulmonary tuberculosis. Pneumologia 2004;27:690-3.
  19. Xu W-g, Lu w, He H-j, Gu X-r. Randomized control study on domestic fixed-dose combinations in theinitial treatment of smears positive tuberculosis. Zhonghuab Jie He He Hu Xi ZaZhi 2004;27:690-3
  20. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-9.
  21. Zaka-Ur-Rehman Z, Jamshaid M, Chaudhry A. Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients. Pak J Pharm Sci 2008;21:185-94.
  22. Zekri Laaroussi. Traitement de la tuberculose par les formes combinées des antituberculeux. Thèse pour le doctorat en Médecine Tunis 1996.